Provided by Tiger Fintech (Singapore) Pte. Ltd.

Akebia Therapeutics

2.26
+0.570033.73%
Post-market: 2.22-0.0400-1.77%19:59 EDT
Volume:13.25M
Turnover:28.51M
Market Cap:533.36M
PE:-9.89
High:2.29
Open:1.77
Low:1.76
Close:1.69
Loading ...

U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis

PR Newswire
·
03 Dec 2024

Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

PR Newswire
·
25 Nov 2024

New Strong Sell Stocks for November 22nd

Zacks
·
22 Nov 2024

Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease

PR Newswire
·
14 Nov 2024

Akebia Therapeutics to Present at the Jefferies London Healthcare Conference

PR Newswire
·
12 Nov 2024

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$5.50

Simply Wall St.
·
09 Nov 2024

Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Price Is Right But Growth Is Lacking After Shares Rocket 41%

Simply Wall St.
·
08 Nov 2024

Akebia Therapeutics Inc (AKBA) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ...

GuruFocus.com
·
08 Nov 2024

Akebia Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary

Reuters
·
07 Nov 2024

Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates

Zacks
·
07 Nov 2024

Akebia Therapeutics: Q3 Earnings Snapshot

Associated Press Finance
·
07 Nov 2024

Akebia Therapeutics Q3 2024 GAAP EPS $(0.10) Misses $(0.06) Estimate, Sales $32.400M Miss $44.507M Estimate

Benzinga
·
07 Nov 2024

Akebia Therapeutics Q3 Basic EPS USD -0.1

THOMSON REUTERS
·
07 Nov 2024

Akebia Therapeutics Inc expected to post a loss of 6 cents a share - Earnings Preview

Reuters
·
04 Nov 2024

Press Release: Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dow Jones
·
02 Nov 2024

Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights

PR Newswire
·
01 Nov 2024